CX3CL1 and breast carcinoma: Mehmeti-Ajradini et al. [95] observed that G-MDSCs isolated from metastatic breast cancer cell patients reduced endothelial expression of CX3CL1 (fractalkine) and prevented infiltration of myeloid immune cells into the tumor.